Cegedim Half-year results 2009 September 2009

Transcription

1 Cegedim Half-year results 2009 September

2 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849 millions of revenue in ,200 employees Market leader World leader in the CRM for the pharmaceutical industry Leading provider of strategic data for the pharmaceutical industry European leader of software for healthcare professionals French leader in management of health flows Customers : All players in the healthcare world All major pharmaceutical companies Doctors, pharmacists and paramedics in Europe Insurers and healthcare mutuals in France 2

3 First half-year 2009 Full compliance with banks covenants 6 months in advance 3

4 Healthcare: A steady long-term growth Healthcare continues spending growth Ageing population Global demographics growth Incremental growth of the pharmaceuticals market between $ billions USA China Higher sales of drugs continues India France Japan U.K. Canada Brazil Germany Reducing of hospitalization costs through the use of drugs Expanding the use of drugs from cure to prevention Source Mc Kinsey& Company : 35 to 40 new drugs introduced per year. Source : McKinsey Big pharma companies should launch more products per year between 2006 and 2012 than during the previous 4 years. Source: Datamonitor Need for a high level of marketing spending 4

5 Emerging countries Growth factors Increase of incomes and emergence of middle-class households Improvement of medical infrastructure Rising of chronic diseases (cardiovascular, obesity, diabetes, cancer, asthma) Setting health insurance Adoption of product patents Cegedim Only specialized player on the market Global presence Largest R&D budget on its niche 5

6 Global presence Split of H revenues 6

7 Main Group hosting and R&D centers Largest Hosting facilities and R&D team in the CRM Pharma industry 800 employees 37 % in France, 38 % in India, 13 % in the US and 10 % in Asia 8 % of revenues devoted to R&D Able to respond to global and local clients needs 7

8 Cegedim provides solutions at every stage of drug lifecycle 8

9 Cegedim serves all the healthcare value chain 9

10 CRM and strategic data 10

11 Cegedim s solutions dedicated to pharmaceutical companies 11

12 Cegedim : Positioning at the center of drug world Delivery and sales Pharmaceutical Companies Promotion Wholesalers Data Data Medical Reps Pharmacies Data Data Doctors Products Patients Prescription 12

13 A market share in continuous progression 40% 35% 30% 25% 20% 15% More than 200,000 user in the pharmaceutical industry (Presence in more 80 countries) 10% 5% 0% Evolution of world CRM market share World CRM market share US CRM market share World OneKey market share 13

14 Market trends are opportunities for Cegedim New drugs concern specialties and requires the use of promotional tools ever more sophisticated Product pipeline by 2015 Others 29% Oncology 27% Outsourcing of IT, compliance and databases Increase of regulatory requirements Cardiovascular 7% Gastrointestinal 10% Anti-infective 10% Neuropsychiarty 17% Need of CRM solutions to increase sale force effectiveness KAM, KOL, Analyses, market research, 70% concentrated in 5 therapeutic areas. Source: McKinsey & Company Data are a cornerstone Need for best data in order to optimize the knowledge of 75% prescribers and patients behavior. Without update, data quality decays rapidly 100% 50% 25% 0% Bad Good # of months 14

15 Key customer wins/renewals in 2009 Leading Biotech company EU / Mobile Intelligence SaaS in 32 countries Bristol Myers Squibb US / Support services extension Mobile Intelligence in Neuroscience Sanofi aventis Global / Agreement for Mobile Intelligence as worldwide platform Mid-size pharma companies US / Mobile Intelligence SaaS for KOL and KAM 2 Top 10 pharma company & 1 leading biopharma US / Compliance solutions Auxilium US / Mobile Intelligence SaaS Global food company Europe / Hosting Numerous contracts in OTC Europe / One of the most dynamic segments of the pharmacy market 15

16 Growth factors Sign global contracts Extend our services to all countries (Compliance, Data, Market research ) Extend to other healthcare market our expertise Animal health, consumer health, medical device, health nutrition, Continue to expand our solution of outsourcing of IT infrastructures Release of MI version 5.0 in early September Simplified customization and configuration seamless integration with OneKey) Extend OneKey services with new products Authentication, web access 16

17 Healthcare professionals 17

18 Healthcare professionals Growth factors Interoperability between software Dematerialization of patient data Need for exchange of information between healthcare professionals Qualitative improvement of medical practice Medical control of healthcare spending 18

19 Healthcare professionals 19

20 Insurances and services 20

21 Insurances and services Software publishing and flows management Publishing sector specific software packages Outsourcing of software solutions for health insurance Management of healthcare flows (250 millions EDI flow per year) Management of healthcare billing and payment flows Services related to front office Growth factors Breakeven of the data flow management platform Willingness of governments to improve the efficiency of healthcare system Merger / concentration Dematerialization Development in Morocco 21

22 Growth strategy Pharmaceutical companies Extend European SaaS model to the US Develop OneKey business in the US Develop business in emerging countries Adapt of outsourcing offer Adapt our products to new needs of sale forces Extend to other healthcare and not healthcare market our expertise External growth Healthcare professionals Expand in US Take advantage of Obama s plan External growth Insurances Development in Morocco Improve product offering Increase the value chain Integration: Become THE platform of flows in France 22

23 Financial Information 23

24 Financial information Good revenue mix By regions By activities By customers Good revenue visibility Strong recurring revenue model Multi-year contracts High switching costs Financial situation under control Net cash of 69M as of June 30 th Full compliance with bank covenants Integration and restructuring plans Positive impact on margins from 1H 2009 R&D optimization 24

25 Growth factors Revenue drivers Market growth Commercial success Successful integration of Dendrite Worldwide player Cegelease Health reforms Margin drivers Integration and restructuring plans R&D optimization Standardization of the CRM product Set up of CHS Strong performance form Insurances and services 25

26 Customer mix Only one customer represents more than 3% of the Group s revenue Sanofi aventis: 6 % of 2008 Group s revenue Top 5 customers 16 % of 2008 Group s revenue Top 10 customers 23 % of 2008 Group s revenue Strong customer loyalty High switching cost High levels of customer satisfaction Long term contracts 26

27 First half-year 2009 revenues: 5% increase L-f-L * (*) at constant scope and exchange rates. 27

28 H margin 28

29 H Operating margin by sectors (*) Operating profit restated with exceptional charges (IFRS) and restructuring and integration costs 29

30 H income statement 30

31 H income statement 31

32 H Balance sheet 32

33 Covenants overview In millions of euros H Total bank borrowings Total cash Net bank loans Net bank debt / Contractual* EBITDA Contractual* EBITDA / Financial expenses (senior debts) * As defined in the covenants of the financial contratc for the acquisition of Dendrite 33

34 H Cash flow 34

35 2009 Outlook Cegedim remains right on tract, is meeting its repayment deadlines and developing new products suited to market needs. As a result, we confirm our 2009 revenue growth target of approximately 6%. Furthermore, all of the cost-cutting measures adopted in 2008 are expected to continue to boost margins, all other things being equal. 35

36 Cegedim market price 105,00 Financial press release 95,00 Q2 07 TO H1 07 Roadshow in Europe Roadshow in the USA 85,00 Q3 07 TO 75,00 65,00 55,00 Q4 07 TO Q1 08 TO Q2 08 TO H1 08 H1 09 Q2 09 TO 45, Results Q3 08 TO 2008 Results RS USA Q1 09 TO 35,00 25,00 Q4 08 TO 31/07/ /12/ /04/ /08/ /12/ /04/ /08/

37 Cegedim share Shareholders Stock information Quotation: NYSE Euronext Paris - compartiment B Quotation date: April 1995 ISIN code: FR Reuters code: CGDM.PA Bloomberg code: CGM Closing date: December, 31 Share value at first listing: 9.52 euros Number of shares at 08/31/2009: 9,331,449 Analysts coverage CA Cheuvreux : Michaël Beucher CM-CIC Securities : Jean-Pascal Brivady Gilbert Dupont : Nicolas Montel / Guillaume Cuvillier Market capitalization at 09/24/2009 : 606 million euros Natixis Securities : Richard Beaudoux Oddo & Cie : Xavier-Emmanuel Pingault Société Générale : Patrick Jousseaume 37

38 Appendix 38

39 Cegedim s history 39

40 No direct competitors on the entire value chain Leasing Mutual software Flows Compliance Pharmacists software Doctors software Market research Strategic data Data base Integration Services CRM SaaS CRM Licence Local actor 40